Abstract. Glycogen synthase kinase 3β (GSK 3β), a multifunctional serine and threonine kinase, plays a critical role in a variety of cellular activities, including signaling transduction, protein and glycogen metabolism, cell proliferation, cell differentiation, and apoptosis. Therefore, aberrant regulation of GSK 3β results in a broad range of human diseases, such as tumors, diabetes, inflammation and neurodegenerative diseases. Accumulating evidence has suggested that GSK 3β is correlated with tumorigenesis and progression. However, GSK 3β is controversial due to its bifacial roles of tumor suppression and activation. In addition, overexpression of GSK 3β is involved in tumor growth, whereas it contributes to the cell sensitivity to chemotherapy. However, the underlying regulatory mechanisms of GSK 3β in tumorigenesis remain obscure and require further in-depth investigation. In this review, we comprehensively summarize the roles of GSK 3β in tumorigenesis and oncotherapy, and focus on its potentials as an available target in oncotherapy.

Contents
1. Introduction
2. Regulation of GSK 3β
3. Role of GSK 3β in tumorigenesis
4. Role of GSK 3β in oncotherapy
5. GSK 3β inhibitors in antineoplastic treatment
6. GSK 3β in cancer immunotherapy
7. Conclusion

1. Introduction

Glycogen synthase kinase 3 (GSK3), a member of the mitogen-activated protein (MAP) kinase superfamily, has two highly conserved homologous isoforms, GSK 3α (51 kDa) and GSK 3β (47 kDa). Discovered in 1980, both of these two isoforms are multifunctional serine and threonine protein kinases, and they are widely expressed in all eukaryotes (1-3). Encoded by the human chromosome 19q13.2 and 3q13.33, respectively, GSK 3α and GSK 3β share 98% identical sequences in their kinase domains (4,5). Despite structural similarities, their functions are different by phosphorylation at distinctive sites (5). For the activation of GSK 3α and GSK 3β, tyrosine 279 (Y279) and tyrosine 216 (Y216) are phosphorylated by upstream signaling molecules respectively, and these two sites are located at the T-loop of GSK 3 (activation domain) (Fig. 1). Notably, GSK 3α and GSK 3β are inactivated by site-specific phosphorylation, which is tightly controlled by diverse mechanisms (6). All these mechanisms for the inactivation of GSK 3α at Ser21 and GSK 3β at Ser9 have been revealed to be attributed to the phosphoinositide3 kinase (PI3K)-dependent mechanism (7). Activated by PI3 kinase, protein kinase A (PKA), protein kinase B (PKB) (also termed as Akt), protein kinase C (PKC) and p90Rsk contribute to the inactivation of GSK 3, which ultimately leads to the dephosphorylation of GSK 3 substrates (8). Initially, the inactivation of GSK 3 was considered to be a critical mediator in glycogen metabolism and insulin signaling, since it could give rise to the phosphorylation of glycogen synthase and could promote glycogen synthesis (9). Currently, emerging
evidence has demonstrated that GSK 3, particularly GSK 3β, is well-established as a vital component in signaling pathways of cell regulation, involving cell proliferation, differentiation, motility, apoptosis and the cell cycle (1,2,10). As an attractive therapeutic target, GSK 3 has been revealed to be implicated in the pathogenesis of numerous human diseases, such as diabetes, inflammation, Alzheimer's disease, cardiovascular and bipolar disease (11-13). In addition, GSK 3β has been demonstrated to be a transcription factor regulating tumor progression, invasion and metastasis (14,15). In different types of cancers, GSK 3β plays a controversial role as a tumor suppressor or a tumor promoter (16,17). Furthermore, GSK 3β has been demonstrated to be a key regulator of chemo-resistance and radio-resistance in tumor treatment (18,19). Therefore, the regulatory roles of GSK 3β in tumor development and progression require elucidation. In addition, to date, it has been revealed that GSK 3β inhibitors are potential therapeutic drugs in cancer therapy, thus, pre-clinical and clinical studies of GSK 3β inhibitors are also presented.

2. Regulation of GSK 3β

It has been revealed that the activity of GSK 3β could be regulated in a substrate-specific manner, which comprises four key mechanisms: Phosphorylation, subcellular localization, the formation of protein complexes and the phosphorylation status of GSK 3β substrates (12). Among them, phosphorylation is deemed to be the most important regulatory mechanism of GSK 3β, which would lead to the inactivation of GSK 3β at Ser9. The activated PI3K/Akt signaling pathway phosphorylates GSK 3β at inhibitory serine residues and the phosphorylation may result in the activation of transcription factors in response to carcinogenesis, for instance activating protein-1 (AP-1), cyclic adenosine monophosphate (cAMP)-response element binding protein (CREB), β-catenin, c-Myc and nuclear factor-kappa (NF-κB) (1,20). In addition, upstream proteins of GSK 3β, including P70S6 kinase, extracellular signal-regulated kinases (ERKs), p90sk (also called MAPKAP kinase-1), protein kinase C (PKC) and cAMP-dependent protein kinase [protein kinase A, (PKA)], could lead to the inactivation of GSK 3β (1,21,22). Each regulatory kinase is influenced by GSK 3β distribution, while scaffolding proteins could restrain the interaction between kinases (6) (Fig. 2A). It has been established that the phosphorylation of tyrosine at 216 site of GSK 3β (Tyr216) is regulated by calcium-dependent tyrosine kinase, proline-rich tyrosine kinase 2 (PYK2), cAMP-activated protein tyrosine kinase, Zaphod kinase 1 (ZAK1) or Fyn (23,24). Additionally, phosphorylation of GSK 3β at Tyr216 is regulated by mitogen-activated protein kinase (MEK1/2) (25). Generally, GSK 3β is classified as an active constituent enzyme in the cytoplasm of resting cells. When activated, GSK 3β is accumulated in the nucleus and mitochondria (26) (Fig. 2B). Notably, by activating the genes of downstream transcription factors and recruiting the aggregation of these transcription factors, nuclear translocation of GSK 3β regulates a great number of transcription factors (27). More than 40 proteins are downregulated by GSK 3β. These proteins are involved in a broad range of cellular processes, including protein synthesis, cell differentiation, proliferation and apoptosis (2,10,14). Substrates that are closely related to tumorigenesis and cancer development tend to be dephosphorylated. In the canonical Wnt signaling pathway, β-catenin, an important element of Wnt signaling, is controlled by GSK 3β (28). With the absence of Wnt signaling, activated GSK 3β forms a complex with adenomatous polyposis coli (APC) and the transcriptional co-activator β-catenin, and therefore the complex binds with the scaffolding protein Axin. This newly formed complex enables GSK 3β to phosphorylate β-catenin and leads to the degradation of β-catenin. Conversely, the Wnt signaling pathway could inactivate GSK 3β and prevent the phosphorylation of β-catenin by GSK 3β (29). In addition, β-catenin binds to the T-cell factor (TCF)/lymphocyte enhancer factor (LEF), and ultimately promotes the transcription of TCF/LEF transcription factor family-related genes, including proto-oncogenes, such as c-Myc, cyclin D1 and the vascular endothelial growth factor (VEGF), as well as genes that regulate cell invasion and migration, including matrix metalloproteinase-7 (MMP-7) (30-32). Therefore, as the upstream gene of β-catenin, GSK 3β plays a pivotal role in cell proliferation, migration, metastasis and differentiation by controlling Wnt signaling. Additionally, other proto-oncogenic or tumor suppressing transcription factors (such as p53) and translation factors are the substrates of GSK 3β. With regard to DNA damage studies, the increasingly activated GSK 3β in the nucleus and mitochondria promotes the expression of the tumor suppressor protein p53, and forms a complex with p53, which enhances the response of p53-induced apoptosis (33,34). Furthermore, GSK 3β directly phosphorylates Kruppel-like factor 6 (KLK6), a zinc-finger transcription factor which is a tumor suppressor, inhibiting the tumor growth by increasing KLK6-mediated growth suppression through p53-independent transactivation of p21 (35) (Fig. 3).

3. Role of GSK 3β in tumorigenesis

For decades, accumulating research has been exploring the role of GSK 3β in human oncology. Based on the studies of the GSK 3β signaling mechanism, the regulation of GSK 3β in cancer progression is intricate (14,36). It has been demonstrated that GSK 3β acts as a tumor suppressor in prostate cancer, by inhibiting androgen receptor-mediated cell growth (37). Conversely, it has been observed in colon cancer cell lines and colorectal cancer patients that the expression levels and the enzyme activities of GSK 3β were higher than normal cells, therefore GSK 3β appears to be a tumor promoter (38). Herein, in order to further elucidate GSK 3β as a potential therapeutic target for various cancers, a comprehensive review about the multiple roles of GSK 3β in tumorigenesis is provided.

**GSK 3β as a tumor suppressor.** Since GSK 3β downregulates numerous proto-oncogenic proteins and cell cycle checkpoint proteins, GSK 3β has been generally recognized as a tumor suppressor by inhibiting cell proliferation (39). Previous studies have demonstrated that PI3K inhibitor LY294002 and tumor suppressor phosphatase and tension homolog deleted on chromosome 10 (PTEN) stimulate GSK 3β-mediated degradation of β-catenin by inhibiting the PI3K/Akt pathway, thereby inhibiting the progression of prostate tumors (40,41). In addition, GSK 3β is phosphorylated and inactivated by the activation of PI3K/Akt pathway, and therefore, inactivated
GSK 3β prevents the phosphorylation of cyclin D1, inhibits the expression of cyclin D1 gene (CCND1), and accumulates cyclin D1 at the nucleus of breast cancer cells (42). Moreover, it has been revealed that adiponectin could prevent Akt-induced
phosphorylation of GSK 3β and decrease intracellular accumulation and nuclear activity of β-catenin, subsequently reducing the expression of cyclin D1 (43). This mechanism leads to the apoptosis of breast cancer cells MDA-MB-231 and T47D, and induces the cell cycle arrest of MDA-MB-231 cells at G0-G1 phase. Additionally, it has been revealed by in vivo experiments that the adiponectin-mediated suppressive effect on the GSK 3β/β-catenin signaling pathway could reduce mammary tumorigenesis in female nude mice (43). Therefore, GSK 3β is perceived as a tumor suppressor in the tumorigenesis and progression of breast cancer (Fig. 4).

Emerging evidence has revealed that GSK 3β phosphorylates various tumor factors (TFs), including cyclin D1, cyclin E, AP-1, c-Jun, p53, p65, Snail, c-Myc and β-catenin, which would facilitate their degradation and prevent them from entering the nucleus. Thereby, their activities are downregulated in oral squamous cell carcinoma (OSCC) (44-51). It has been indicated that activated GSK 3β binds to the mesenchymal Snail gene. Then it inhibits the phosphorylation, degradation and cytoplasmic translocation of Snail, and subsequently inhibits p-cadherin-induced development and homeostasis of epithelial architecture. Consequently, GSK 3β may reverse the p-cadherin-contributed oncogenesis in OSCC (52). In addition, it has been demonstrated that the overexpression of focal adhesion kinase (FAK) may activate NF-κB by inactivating GSK 3β, and therefore promotes cancer cell migration. In addition, the inactivation of GSK 3β has also been revealed to suppress cell apoptosis in pre-invasive and invasive OSCC (51,53,54). Furthermore, as the induction of intracellular reactive oxygen species (ROS) stimulates cell apoptosis (55), constitutively activated GSK 3β has been reported to increase the mitochondrial membrane potential and to promote ROS (56,57). In addition, several matrix metalloproteinases (MMPs) can also facilitate the migration of cancer cells, thereby upregulating and activating tumor factors, such as Snail, AP-1 and NF-κB in OSCC (58,59). Collectively, GSK 3β could be a potential therapeutic target for the treatment of OSCC by suppressing tumorigenesis (Fig. 4).

It has been indicated that the overexpression of macrophage migration inhibitory factor (MIF) is associated with
the development and progression of esophageal squamous cell carcinoma (ESCC) (60,61). Further study has demonstrated that the deletion of MIF attenuates Akt-dependent GSK 3β phosphorylation and restores tumor suppressor activity of GSK 3β in esophageal squamous cell carcinoma. Additionally, GSK 3β phosphorylates various tumor factors, facilitates their degradation, and prevents them from entering the nucleus. GSK 3β, glycogen synthase kinase 3β; PTEN, phosphatase and tension homolog deleted on chromosome 10; AR, androgen receptor; CCND1, cyclin D1 gene; FAK, focal adhesion kinase; MMPs, matrix metalloproteinases; AP-1, activating protein-1.

Figure 4. Tumor inhibitory role of GSK 3β. LY294002, adiponectin and PTEN suppress GSK 3β-participated β-catenin degradation and cell cycle arrest by inhibiting the PI3K/Akt pathway in prostate tumor and breast cancer. The deletion of MIF attenuates Akt-dependent GSK 3β phosphorylation and restores tumor suppressor activity of GSK 3β in esophageal squamous cell carcinoma. Additionally, GSK 3β phosphorylates various tumor factors, facilitates their degradation, and prevents them from entering the nucleus. GSK 3β, glycogen synthase kinase 3β; PTEN, phosphatase and tension homolog deleted on chromosome 10; AR, androgen receptor; CCND1, cyclin D1 gene; FAK, focal adhesion kinase; MMPs, matrix metalloproteinases; AP-1, activating protein-1.

GSK 3β as a tumor promoter. GSK 3β also plays a critical role in tumor cell proliferation. Overexpression of GSK 3β has been observed in various tumor types, including colon, liver, ovarian and pancreatic tumors (14,64). It has been previously reported that GSK 3β inhibitors (SB-216763 and AR-A014418) significantly suppress the growth of patient-derived xenograft (PDX) colon cancer, and GSK 3β inhibitors are anticipated to be therapeutic agents for colon cancer (64). The overexpression of nuclear GSK 3β and the loss of membrane β-catenin are substantially correlated with poor survival, distant metastasis and worse prognosis of colon cancer patients (65). It is further discovered that the formation of nuclear GSK 3β and β-catenin could decrease the transcription of TCF/LEF target gene (66). In addition, it has been clarified that troglitazone, an agonist of peroxisome proliferator activated receptor γ (PPARγ), could suppress the activity of NF-κB by inhibiting the activity of GSK 3β, reducing the expression of G0/G1 phase regulatory proteins including Cdk2, Cdk4 and cyclin B1, and increasing the cleavage of apoptosis-associated proteins, such as caspase-3 and caspase-9 of human colon cancer and prostate cancer (67,68). A previous study has revealed that p53+/+ colorectal cancer cells treated with GSK 3β inhibitor or GSK 3β silencing RNAs could facilitate the increase of p53-dependent apoptosis, instead of cell cycle arrest (69). Furthermore, the activation of PI3K/Akt signaling would result in the inactivation of GSK 3β, which promotes cell growth by inhibiting apoptosis-related proteins including Bcl-2 family in 1, 2-dimethylhydrazine (DMH)-induced colorectal cancer (70). In addition, the overexpression of GSK 3β and the nuclear transcription of NF-κB play critical roles in the survival and proliferation of pancreatic cancer cells (71). However, GSK 3β knockdown has been revealed to decrease the expression of
Bcl-2 and VEGF, and ultimately result in the growth arrest of tumors (72). In addition, by increasing the expression of cyclin D1 and facilitating the proliferation of ovarian cancer cells, activation of GSK 3β could promote the activation of NF-κB and lead to cell cycle entering of tumor cells into the S phase (73). Accumulating evidence has revealed that GSK 3β could affect intracellular glucose metabolism by restraining the p53-, NF-κB- and c-Myc-mediated pathways, and thereafter promote the proliferation and survival of glioblastoma cells and protect them from apoptosis (20,74). Markedly, GSK 3β could transfer from the cytoplasm to the nucleus in glioblastoma (GBM) when stimulated by ionizing radiation (IR), and could bind to p53 binding protein 1 (53BP1) at Ser166. The binding of GSK 3β with 53BP1 results in the increased DNA double-strand break (DSB) repair in GBM after IR (75) (Fig. 5). Notably, GSK 3β inhibitor, SB216763, comparatively decreases the proliferation of GBM cells and induces apoptosis of GBM cells by halting DSB repair. Similarly, it has been revealed that GSK 3β inhibitor could block the NF-κB pathway and reduce the NF-κB-mediated transcription in osteosarcoma (OSA) (76).

However, as the present inhibitors are not specific but targeting both GSK 3α and GSK 3β, the oncogenic role of GSK 3β has been explored by gain and loss-of-function approaches of transgenic mice, including both knockout and knock-in animal models. A study by Kerkela et al revealed that the GSK 3β−/− mice exhibited hypertrophic myopathy, which was caused by cardiomyocyte hyperproliferation with increased expression and nuclear localization of three important regulators of proliferation (GATA4, cyclin D1, and c-Myc) (77). Furthermore, Hoeflich et al reported that disruption of the GSK gene resulted in embryonic lethality caused by severe liver degeneration during mid-gestation with the activation of the transcription factor activation NF-κB, and the apoptotic sensitivity of GSK 3β−/− fibroblasts was a direct consequence of GSK 3β deficiency (78). Using GSK 3β knock-in mice, studies have revealed that GSK-3 supports the maintenance of MLL leukemia cells by promoting continuous degradation of the cyclin-dependent kinase inhibitor p27Kip1 (79,80). In addition, phosphorylation of mTOR, p70S6K, and 4E-BP1 were impaired in GSK 3β knock-in mice (81). Therefore, GSK 3β can be perceived as an oncogenic protein and GSK 3β inhibitors are potential new drugs in cancer therapy.

Figure 5. Molecular pathways revealing how GSK 3β influences tumor sensitivity to different chemo-therapeutic agents. In glioblastoma, GSK 3β inhibition improves temozolomide sensitivity by regulating the Mdm2/P53 and c-Myc/MGMT signaling pathways, which upregulate the methylation of MGMT promoter. Additionally, GSK 3β inhibitor enhances the sensitivity of pancreatic cancer to gemcitabine by negatively regulating the cyclin D1/CDK4/6 complex-dependent phosphorylation of Rb tumor suppressor protein. GSK 3β, glycogen synthase kinase 3β; DNMT3A, DNA methyltransferase 3 alpha; Mdm2, mouse double minute 2; MGMT, O6-methylguanine DNA methyl transferase; TP53INP1, tumor protein 53-induced-nuclear-protein 1; IR, ionizing radiation; 53BP1, p53 binding protein 1; CDK 4/6, cyclin-dependent kinase 4/6; Rb, retinoblastoma; E2F, E2 transcription factor.

4. Role of GSK 3β in oncotherapy

GSK 3β is also considered to be a pivotal mediator in regulating the sensitivity of tumor cells for chemotherapy and radiotherapy. It has been observed that the expression of GSK 3β is significantly increased in paclitaxel-resistant ovarian
carcinoma cell line (SKOV3) (82). Moreover, downregulation of GSK 3β increased the therapeutic effect of 5-fluorouracil (5-FU), abolished cell viability and colony growth, and reduced the xenograft tumor mass in various drug-resistant p53-null colon cancer cell lines, which implies that GSK 3β inhibitor, in combination with chemotherapy, may represent a novel strategy for the treatment of chemotherapy-resistant tumors (83). GSK 3β inhibition was revealed to allow chemo-resistant carcinoma cells to become more susceptible to the synthetic multi-kinase inhibitor (sorafenib) which inhibits cell growth and angiogenesis (84). In addition, the increased expression of GSK 3β phosphorylation at Ser9 has been revealed to promote the chemo-sensitivity in cisplatin-resistant CP70 cells. The pGSK 3β (Ser9) increased the cisplatin resistance of ovarian carcinomas by reducing the GSK 3β regulated stabilization of p53 expression (85). Furthermore, LY294002, a PI3K inhibitor, has been revealed to enhance chemotherapy-induced apoptosis and the cleavage of caspase-8 by promoting GSK 3β dephosphorylation at Ser9 (86). Similarly, in MCF-7 breast cancer cells, selective inhibition of GSK 3β attenuated cytotoxicity induced by histone deacetylase inhibitor trichostatin A (87). Additionally, GSK 3β inhibition also enhanced the sensitivity of glioblastoma cells to radiation (75). In glioblastoma, GSK 3β inhibition improved the therapeutic effect of temozolomide by modulating the expression of O*-methylguanine DNA methyl transferase (MGMT) promoter via c-Myc signaling pathway (74,88). Moreover, GSK 3β inhibitor enhanced the sensitivity of pancreatic cancer to gemcitabine by decreasing the expression of tumor protein 53-induced-nuclear-protein 1 (TP53INP1), a pro-apoptotic stress-induced or DSB repair-mediated p53 target gene, and by downregulating the CDK4/6 complex-dependent phosphorylation of Rb tumor suppressor protein (89,90) (Fig. 5).

Collectively, GSK 3β regulates various responses to chemotherapy among a variety of tumor cell types, which is not entirely consistent with its role as a tumor suppressor or tumor promoter. On the one hand, GSK 3β inhibitor acts as a tumor promoter to attenuate the sensitivity of breast cancer cells to chemotherapy. On the other hand, GSK 3β functions as a tumor promoter for pancreatic cancer and GSK 3β inhibitor enhances the sensitivity of pancreatic cancer cells to chemotherapy. Therefore, the mechanisms of the GSK 3β signaling pathway in tumorigenesis and drug responses are significantly diverse, and require further investigations.

5. GSK 3β inhibitors in antineoplastic treatment

GSK 3β has been revealed to play a critical role in the regulation of a variety of cellular functions, including cell proliferation, differentiation, motility, apoptosis and the cell cycle (1,2,10). In addition, GSK3 inhibitors may be appropriate for the treatment of certain diseases, including diabetes, bipolar disorder, inflammation and certain types of cancer (91). Inhibitors of GSK 3β are categorized as GSK 3β-selective or non-selective and ATP-competitive or non-ATP-competitive (92-121).

Lithium, a well-documented inhibitor of GSK3, can promote phosphorylation of GSK 3β at Ser9 and inhibit the activity of GSK 3ββ by competing with magnesium (Mg2+) rather than ATP or its substrate. It has been indicated that lithium has become a gold standard for the treatment of bipolar mood and nervous disorders (92,93). Additionally, lithium has an effect on embryonic development by promoting the differentiation of epithelial cells, increasi calciium (Ca2+) storage in the bones, and hindering the entering of the cell cycle (94-96). Lithium has been revealed to induce apoptosis in both Jurkat cells and differentiated immortalized hippocampal neurons by stimulating the death domain-containing receptor Fas (97). Notably, the treatment with lithium was revealed to increase the levels of p21WAF1/CIP1 (a protein with anti-apoptotic function) and survivin (a protein that supports the growth of cells by suppressing apoptosis and promoting cell proliferation) in human GBM cells (98). Furthermore, lithium was revealed to inhibit cell motility and compromise the invasive phenotype of v-Src-transformed cells, which was mediated by the activation of phospho-tyrosine phosphatases via the regulation of the cell redox status (99).

To date, several compounds targeting GSK 3 are still under pre-clinical studies, and few of them are in clinical trials (Table 1). The mechanisms of GSK3 inhibition greatly vary. Both lithium and SB216763 have been demonstrated to have effects on tumor growth by inhibiting cell proliferation, however 9-ING-41 tends to induce apoptosis (100). SB216763, an ATP-competitive inhibitor of GSK 3β, has been revealed to downregulate AR-mediated prostate cancer cell growth in vitro and in vivo (101,102). It has also been revealed to potentiate the death ligand-induced apoptotic response in pancreatic cancer cells (PANC1 and MIA PaCa-2) by activating the c-Jun N-terminal kinase (JNK) pathway (103). Similarly, SB-415286, another ATP-competitive inhibitor specific for GSK 3β, was demonstrated to induce the expression of a β-catenin-LEF/TCF regulated reporter gene (104). Its treatment potentiated TRAIL- and CH-11-induced apoptosis in HepG2 cells, and induced growth arrest and apoptosis in multiple myeloma (MM) cells (105,106). Additionally, it decreased the viability of Neuro-2A cells, and induced G2/M arrest (107). Non-ATP competitive GSK 3β inhibitors, including LiCl, TDZD-8 and L803-mts, could also induce significant inhibition of tumor growth (108). A previous study has revealed that TWS119 could reverse the effects of tamoxifen on β-catenin and Snail expression thereby inhibiting GSK-3β/β-catenin activation (109). Furthermore, TWS119 exhibited different effects on CD4+ and CD8+ T cells in tumor-infiltrating lymphocytes (TILs) by stimulating the expansion of naïve T cell and CD8 stem cell-like memory T cells, and inducing CD8+ effector T-cell proliferation in TILs (110). The selective GSK 3β inhibitor, manzamine A, can reduce the metastatic potential of AsPC-1 pancreatic cancer cells and promote TRAIL-induced cell apoptosis (111). Inhibition of GSK 3β with AR-A014418 was also revealed to increase the sensitivity of PANC1 cells to gemicitabine by regulating the Rb/E2F pathway (93) (112).

Notably, 9-ING-41 [benzofuran-3-yl-(indol-3-yl)maleimide], a maleimide-based ATP-competitive small molecule GSK-3β inhibitor, has been demonstrated to be more selective for GSK 3β than for other related kinases (113). In vitro cell line studies and in vivo animal models have revealed the antitumor effects of 9-ING-41 in various cancers, including bladder cancer (114), renal cancer (115), neuroblastoma (116), B-cell lymphoma (117), breast cancer (118) and glioblastoma (119). A previous study on 9-ING-41 revealed
Table I. Specific and non-specific GSK 3β inhibitors.

| Compound       | Specificity | Inhibition mode       | Applications/mechanisms                                                                 | (Refs.) |
|----------------|-------------|-----------------------|----------------------------------------------------------------------------------------|---------|
| Lithium        | Non-specific GSK 3β | Mg<sup>2+</sup> competitive | Bipolar mood and nervous disorders                                                      | (96)    |
| SB216763       | Non-specific GSK 3β | ATP competitive        | Inhibits AR-dependent reporter gene activity                                           | (96-99) |
| SB415286       | Non-specific GSK 3β | ATP competitive        | Induces the accumulation of cells in the G2/M phase of the cell cycle and apoptosis in Neuro-2A cells | (100-103)|
| TDZD-8         | Specific GSK3β | Non-ATP competitive    | Activates the ERK pathway and increases expression of EGR-1 and p21 genes, which suppresses the proliferation of glioblastoma cells | (104)   |
| L803-mts       | Specific GSK3β | Non-ATP competitive    | Significant inhibition of tumor growth in mouse xeno graft models of prostate cancer     | (104)   |
| TWS119         | Specific GSK3β | ATP competitive        | Decreases ATP production in cells, resulting in the increase in the AMP/ATP ratio and triggers AMPK in prostate cancer cells | (105 and 106)|
| Manzamine A    | Specific GSK3β | Non-ATP-competitive    | Inhibits autophagy and tumor growth                                                   | (107)   |
| AR-A014418     | Specific GSK3β | ATP competitive        | Mainly suppresses the growth of pancreatic cancer by reducing the phosphorylation of GSK3α with concomitant Notch1 reduction | (86 and 108)|
| 9-ING-41       | Specific GSK3β | ATP-competitive        | Inhibits the growth of various cancers and attenuates the progression of pulmonary fibrosis | (109-117)|

GSK 3, glycogen synthase kinase 3; AR, androgen receptor; ERK, extracellular signal-regulated kinase; EGR-1, early growth response-1; AMP, adenosine monophosphate; ATP, adenosine triphosphate; AMPK, AMP-activated protein kinase.

that it upregulates the phosphorylation of the inhibitory serine residue of GSK 3β in ovarian cancer cells, and subsequently induces the apoptosis of ovarian cancer cells (120). A study from Ugolkov et al demonstrated that 9-ING-41 leads to the regression of patient-derived xenograft (PDx) tumors from metastatic pleural effusions obtained from patients with progressive, chemo-refractory breast cancer (118). Their group also revealed that 9-ING-41 significantly enhanced 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) antitumor activity in chemo-resistant PDx models of GBM by decreasing tumor size and increasing overall survival (119). In addition, 9-ING-41 could attenuate the progression of pulmonary fibrosis by improving lung functions and inhibition of myofibroblast differentiation in lung fibroblasts ex vivo and pulmonary fibrosis in vivo (121). With significant pre-clinical antitumor activity, 9-ING-41 is under phase 1/2 clinical trials in patients with refractory hematologic malignancies or solid Tumors (Clinical Trials ID: NCT03678883) (https://clinicaltrials.gov/ct2/show/NCT03678883).

6. GSK 3β in cancer immunotherapy

A previous study has revealed the immune-regulatory role of GSK 3β via the phosphorylation of two important transcription factors, NF-κB and CREB (122). Moreover, the phosphorylation of these two transcription factors could result in proteasomal degradation. In addition, the inactivation of GSK 3β has been revealed to lead to the nuclear transfer of NF-κB and CREB, which stimulate the secretion of inflammation-related cytokines (123,124).

For the innate immune system, the NK lymphocyte plays a critical role, and its activation relies on specific receptors including NKG2D/2B4 or NKG2D/DNAM-1. However, these activators may inhibit the activity of GSK 3β via the ERK or Akt signaling pathways (125,126). Studies on GSK 3β knockdown and its inhibitors revealed that the inactivation or silencing of GSK 3β leads to NK cell activation and enhanced function (127,128). A study on MM cells indicated that the inhibition of GSK3 upregulated MICA transcription and translation both in MM cell lines and in tumor cells isolated from MM patients, without significant effects on the basal expression of the MICB and DNAM-1 ligand poliovirus receptor/CD155. Moreover, GSK 3 inhibitors increased NK-mediated cytotoxicity of MM cells by activating NK cell degranulation. In addition, combined with lenalidomide or melphalan, treatment with GSK-3 inhibitors induced MICA expression and increased NK cell-mediated tumor killing by promoting NKG2D recognition in NK cells. Therefore, GSK-3 inhibitors could be novel therapeutic drugs targeting MICA expression and improving immune response in MM patients (129). For the acute myelogenous leukemia (AML) patients, NK cells expressed high levels of GSK 3β. Therefore, treatment with the GSK 3 inhibitors or the genetic inactivation of the GSK 3 led to the increased activity of NK cells to kill AML cells. Furthermore, GSK3 inhibition promoted the formation AML-NK cell conjugates by upregulating LFA expression on NK cells and by inducing ICAM-1 expression on AML cells (130). Another study on GSK 3 revealed that its inhibitor significantly upregulated transcription factors associated with late-stage NK-cell maturation, such as E-box binding
homeobox 2 (ZEB2), PR/SET domain 1 (PRDM1), and T-box 21 (TBX21) and subsequently increased CD57 acquisition and maturation. In addition, NK cells, which were expanded \textit{ex vivo} in the presence of GSK3 inhibitor, produced more TNF and IFN-γ, natural cytotoxicity and antibody-dependent cellular cytotoxicity (131). Therefore, currently, there are several ongoing clinical trials of adaptive NK cells treated with GSK 3 inhibitors for relapsed AML, ovarian cancer as well as other solid tumors.

Accumulating evidence has demonstrated the significance of GSK 3 in T cells. Because it is constitutively active in resting T cells, GSK 3 acts as a negative regulator of T-cell response by inhibiting CD8+ T-cell proliferation and IL-2 production (132). The inactivation of GSK 3 can specifically downregulate PD-1 expression by enhancing CD8+ CTL function and clearance of lymphoma cells (133,134). Additionally, GSK-3 inhibition was revealed to be as effective as anti-PD-1 and PD-L1 blocking antibodies in suppressing the growth of melanoma and lymphoma in mouse models (135). Therefore, GSK-3 was revealed as a central regulator of PD-1 expression. Recently, the same group revealed that GSK-3 also negatively regulated lymphocyte activation gene-3 (LAG-3) expression on CD4+ and CD8+ T cells. The combination of GSK-3 inhibitor with LAG-3 blockade resulted in the suppression of B16 melanoma growth and enhancement of tumor clearance, by increasing the expression of the transcription factor T-bet and binding with the LAG-3 promoter, and subsequently increasing granzyme B and interferon-γ1 expression (136). GSK 3β inhibition has been reported to increase the tumor cell cytotoxic capacity of CD8+ memory stem T cells \textit{in vitro} against gastric cancer cells (137). Moreover, the inactivation of GSK 3β has been revealed to stimulate iTreg differentiation and increase the suppressive activity via the activation of the TGF-β/Smad3 signaling pathway (138). Furthermore, treatment of GBM-specific IL-13 CAR-T cells with the GSK 3 inhibitor resulted in reduced PD-1 expression, increased T cell survival and proliferation. Therefore, GSK 3 inactivation has also been revealed to contribute to the tumor treatment in CAR-T cell immunotherapy (139). Because the polarized-M2 phenotype of macrophages affects tumor growth, invasiveness, angiogenesis (140), and GSK 3β has been reported to enhance the polarization of microglia toward M2 (141), GSK 3β may be the potential therapeutic target for cancer immunotherapy. Collectively, these studies revealed that GSK 3 inhibition could be a new immunotherapeutic strategy for oncology.

7. Conclusion

It has been widely acknowledged that GSK 3β is involved in tumorigenesis, cancer progression and metastasis. However, there are still controversies about the role of GSK 3β as a tumor suppressor or tumor promoter. GSK 3β may function as a tumor suppressor which inhibits neoplastic growth in prostate, oral and lung cancer when overexpressed or activated (51,142-144). Conversely, GSK 3β has also been revealed to facilitate carcinogenesis, and is recognized as a ‘tumor promoter’ in colon, pancreatic and ovarian cancers (65,89,90,120,145). Therefore, based on its pivotal role in tumorigenesis and tumor progression, GSK 3β is predicted to be a clinical prognostic indicator for certain malignant cancers. In conclusion, a more comprehensive understanding of GSK 3β would be comparatively beneficial to disease therapy. Targeting GSK 3β may be an ideal therapeutic strategy for malignant tumors that are characterized by infinite proliferation, metastasis and chemo-resistance, thus providing significant insight for the further research of tumor treatment.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81802504), the National Key Research and Development Program of China (grant no. 2020YFC2005500), the Key Research and Development Program of Science and Technology of the Department of Sichuan Province (grant no. 2019YFS0514) and the Sichuan Medical Association (grant no. Q19037).

Availability of data and materials

Data sharing is not applicable to this article, as no datasets were generated or analyzed during the present study.

Authors’ contributions

YW conceived and designed the review. RH and SD wrote the paper. TL and XX prepared the figures and table. YW reviewed and edited the manuscript. All authors read and approved the manuscript, and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

This review does not contain any studies with human participants or animals performed by any of the authors.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Grimes CA and Jope RS: The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65: 391-426, 2001.
2. Doble BW and Woodgett JR: GSK-3: Tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175-1186, 2003.
3. Embi N, Rylatt DB and Cohen P: Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107: 519-527, 1980.
4. Woodgett JR: Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9: 2431-2438, 1990.
5. Thotala DK and Yazlovitskaya EM: GSK3B (glycogen synthase kinase 3 beta). Atlas Genet Cytogenet Oncol Haematol 15: 7-10, 2011.
6. Jope RS and Johnson GV: The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95-102, 2004.
7. Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR and Mills GB: Phosphorylation and inactivation of glycogen synthase kinase-3beta protein kinase A. Proc Natl Acad Sci USA 97: 11960-11965, 2000.
8. Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789, 1995.
9. Summers SA, Kao AW, Kohn AD, Backus GS, Roth RA, Pessin JE and Johnson GM: The role of glycogen synthase kinase-3beta in insulin-stimulated glucose metabolism. J Biol Chem 274: 17934-17940, 1999.
10. Jacobs KM, Bhave SR, Ferraro DJ, Jaboin JJ, Hallahan DE and Thotala D: GSK-3β: A bifunctional role in cell death pathways. J Cell Biochem 95: 17967012, 2005.
11. Amar S, Belmaker RH and Agam G: The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases. Curr Pharm Des 32: 577-595, 2007.
12. Luo J: The role of GSK3beta in the development of the central nervous system. Front Biol (Beijing) 7: 212-227, 2012.
13. Luo J: Glycogen synthase kinase-3beta (GSK3β) in tumorigenesis and cancer chemotherapy. Cancer Lett 273: 194-200, 2009.
14. Chiara F and Rasola A: GSK‑3 and mitochondria in cancer cells. Front Oncol 3: 16, 2013.
15. Naito S, Bilim V, Yuuki K, Ugolokov A, Motosayama T, Nagaoka A, Kato T and Tomita Y: Glycogen synthase kinase-3beta: A prognostic marker and a potential therapeutic target in human bladder cancer. Int J Clin Oncol 16: 5124-5132, 2010.
16. Tang QL, Xie XB, Wang J, Chen Q, Han AJ, Zou CY, Yin JQ, Kato T and Tomita Y: Glycogen synthase kinase-3beta: A prognostic marker and a potential therapeutic target in human bladder cancer. J Biol Chem 279: 32444-32452, 2004.
17. Shokoori A, Ougolov A, Yu ZW, Zhang B, Modarressi MH, Billiat-Faudeau DD, Mau Y and Minamoto T: Deregulated GSK3beta activity in colorectal cancer: Its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 334: 1365-1373, 2005.
18. Takahashi-Yanaga F and Sasaguri T: GSK-3beta regulates cyclin D1 expression: A new target for chemotherapy. Cell Signal 20: 581-589, 2008.
19. Verras M and Sun Z: Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett 237: 22-32, 2006.
20. Sharma M, Chuang WW and Sun Z: Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear-beta-catenin accumulation. J Biol Chem 277: 30935-30941, 2002.
21. Quintayo MA, Munro AF, Thomas J, Kunkler IH, Jack W, Kerr GR, Dixon JM, Chetty U and Bartlett JM: GSK3β and cyclin D1 expression predicts outcome in early breast cancer patients. Breast Cancer Res Treat 136: 161-168, 2012.
22. Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, Wu D, Cooper GJ and Xu A: Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in vivo. J Biol Chem 282: 13551-13560, 2006.
23. Barul R, Patnaik S and Das BR: Co-overexpression of p53 and c-myc proteins linked with advanced stages of betel- and tobacco-related oral squamous cell carcinomas from eastern India. Eur J Oral Sci 106: 907-913, 2010.
24. de Sousa SO, Mesquita RA, Pinto DS Jr and Gutkind SJ: Immunolocalization of c-Fox and c-Jun in human oral mucosa and in oral squamous cell carcinoma. J Oral Pathol Med 31: 78-81, 2002.
25. Franz M, Spiegel K, Umbrecht C, Richter P, Codina-Carret C, Berndt A, Altendorf-Hofmann A, Koscielny S, Hyckel P, Kostakioti H, et al: Expression of Sirtuin is associated with myofibroblast phenotype development in oral squamous cell carcinoma. Histochim Cell Biol 131: 651-660, 2009.
26. Iwai S, Katagiri W, Kong C, Ameakwa S, Nakazawa M and Yura Y: Mutations of the APC, beta-catenin, and axin I genes and topoisomerase II alpha expression in oral squamous cell carcinoma. J Cancer Res Clin Oncol 131: 773-782, 2005.
27. Buss H, Dörrie A, Schmitz ML, Frank R, Livingstone M, Resch K and Kracht M: Phosphorylation of serine 468 by Jnk signals and regulates basal NF-κB activity. J Biol Chem 279: 495-497, 2004.
28. Goto H, Kawano K, Kobayashi I, Sakai H and Yanagisawa S: Expression of cyclin D1 and GSK-3beta and their predictive value of prognosis in squamous cell carcinomas of the tongue. Oral Oncol 38: 549-556, 2002.
29. Okumura A, Bharat AC, Satoh D and Das BC: Transactivation and expression patterns of Jun and Fos/AP-1 super-family proteins in human oral cancer. Int J Cancer 126: 819-829, 2010.
51. Mishra R: Glycogen synthase kinase 3 beta: Can it be a target for oral cancer. Mol Care 9: 144, 2010.
52. Bauer K, Dowejo A, Bosserhoff AK, Reichert TE and Bauer RJ: Epithelial-mesenchymal transition in oral squamous cell carcinoma by GSK-3 beta-mediated Snail phosphorylation. Carcinogenesis 30: 1781-1788, 2009.
53. Kornberg LF: Focal adhesion kinase expression in oral cancers. Head Neck 20: 634-639, 1998.
54. Ko BS, Chang TC, Chen CH, Liu CC, Kuo CC, Hsu C, Shen YC, Chen TL, Hsiao K, Chang CC, et al: Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sci 86: 199-206, 2010.
55. Takeuchi H, Taoka R, Mneje CO, Jinesh G, Safe S and Kamat AM: CDDO-Me decreases specificity protein transcription factor expression in head and neck squamous cell carcinoma induced by reactive oxygen species. Urol Oncol 34: 337.e1-e18, 2016.
56. Miller WP, Toro AL, Barber AJ and Dennis MD: REDD1 Activates a ROS-generating feedback loop in the retina of diabetic mice. Invest Ophthalmol Vis Sci 60: 2369-2379, 2019.
57. Deng S, Dai G, Chen S, Nie Z, Zhou J, Fang H and Peng H: Dexamethasone induces osteoblast apoptosis through ROS-P13K/AGK/GSK3beta signaling pathway. Biomed Pharmacother 110: 602-608, 2019.
58. Zsobor BL, Silverman SS Jr and Kramer RH: Adhesive mechanisms regulate metastasis and tumor invasion in oral cancer. Crit Rev Oral Biol Med 12: 499-510, 2001.
59. Erdem NF, Carlson ER, Gerard DA and Ichiki AT: Characterization of 3 oral squamous cell carcinoma cell lines with different invasion and/or metastatic potentials. J Oral Maxillofacial Surg 58: 1725-1730, 2000.
60. Zhao J and Liao K: Expression of macrophage migration inhibitory factor in esophageal squamous cell carcinoma and normal esophageal tissue. Acta Acad Med Mil Tertiae 29: 740-742, 2008.
61. Liu RM, Sun DN, Jiao YL, Wang P, Zhang J, Wang M, Ma J, Sun M, Gu BL, Chen P, et al: Macrophage migration inhibitory factor promotes tumor aggressiveness of esophageal squamous cell carcinoma via activation of Akt and inactivation of GSK3beta. Cancer Lett 412: 289-296, 2018.
62. Wang H, Wang HS, Zhou BH, Li CL, Zhang F, Wang XF, Zhang G, Bu XZ, Cai SH and Du J: Epithelial-mesenchymal transition (EMT) induced by TNF-alpha requires AKT/GSK-3beta-mediated stabilization of snail in colorectal cancer. PLoS One 8: e56664, 2013.
63. Kao SH, Wang WL, Chen CY, Chang YL, Wu YY, Wang YT, Wang SP, Nieszvitski AI, Chen YJ, Hong TM and Yang PC: GSK3beta controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene 33: 3172-3182, 2014.
64. Shakoori A, Mai W, Miyashita K, Yasumoto K, Takahashi Y, Ko BS, Chang TC, Chen CH, Liu CC, Kuo CC, Hsu C, Shen YC, Higashi T, Ishigaki Y, Endo Y, Takino T, Sato H, Nishimura H, Nakamura O, Yamagami Y, Mori R, Morie H, Horie R, Fukushima N and Yamamoto T: GSK-3 inhibitor inhibits cell proliferation and induces apoptosis in human osteosarcoma cells. Oncol Rep 35: 2348-2354, 2016.
65. Kerkela R, Kockeritz L, Macaulay K, Zhou J, Doble BW, Beahm C, Green T, Woulfe K, Trivedi CM, Woodgett JR, et al: Deletion of GSK-beta in mice leads to hyperthermic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest 118: 3609-3618, 2008.
66. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O and Woodgett JR: Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406: 86-90, 2000.
67. McManus EJ, Sakamoto K, Armit JJ, Ronaldson L, Shipton N, Marquez R and Alessi DR: Role that phosphorylation of GSK3beta plays in insulin and Wnt signalling defined by knockin analysis. Nature 455: 295-299, 2008.
68. Wang Y, Smith KS, Murphy M, Piloto O, Somerville TC and Cleary ML: Glycogen synthase kinase 3 in MLL leukemia maintenance and targeted therapy. Nature 455: 1205-1209, 2008.
69. Vigneron F, Dos Santos P, Lemoine S, Bonnet M, Tariosse L, Courthial F, Duplaa C and Jaspard-Vinassa B: GSK-3beta at the crossroads in the signalling of heart preconditioning: Implication of mTOR and Wnt pathways. Cardiovasc Pathol 90: 49-56, 2011.
70. Fu Y, Hu D, Qiu J, Xie Y, Ye F and Lu WG: Overexpression of glycogen synthase kinase-3 in ovarian carcinoma cells with acquired paclitaxel resistance. Int J Gynecol Cancer 21: 439-444, 2011.
71. Grasselli E, Narloch R, Federzoni E, Lanzano P, Visco V, Giovanni R, Romano G, Masiero L, Leone BE, Bonin S, et al: Inhibition of GSK3beta bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy. Clin Cancer Res 19: 3820-3831, 2013.
72. Kazemzadeh H, Bilim VN, Ugolkov AV, Yuuki K, Naito S, Nagaoka A, Kato T and Tomita Y: GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC). Biochem Biophys Res Commun 423: 490-495, 2013.
73. Cai G, Wang J, Xin X, Ke Z and Luo J: Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells. Int J Oncol 31: 657-662, 2007.
74. Beurel E, Kornprobst M, Blivet-Van Eggeboom MJ, Cadoret A, Capeau J and Desbois-Mouthon C: GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis. Int J Oncol 37: 215-222, 2005.
75. Alao JP, Stavropoulou AV, Lam WF and Coombes RC: Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A on MCF-7 breast cancer cells. Mol Cancer 2011: 2188.19, 2011.
76. Pyko IV, Nakada M, Sabit H, Teng L, Furuyama N, Hayashi Y, Nakawaki K, Minamoto T, Fedulov AS and Hamada J: Glycogen synthase kinase 3beta inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. Carcinogenesis 34: 2206-2217, 2013.
77. Shimasaki T, Ishigaki Y, Nakamura Y, Takata T, Nakaya N, Nakajima H, Sato I, Zhao X, Kitano A, Kawakami K, et al: Glycogen synthase kinase 3beta inhibition sensitizes pancreatic cancer cells to gemcitabine and Gastroenterol 47: 321-332, 2012.
78. Kitano A, Shimasaki T, Chikan Y, Nakada M, Hirose M, Higoshi T, Ishigaki Y, Endo Y, Takino T, Sato H, et al: Ablation of glycogen synthase kinase 3beta is involved in pancreatic cancer cell invasion and resistance to therapy. PLoS One 8: e55289, 2013.
79. Biegel M and Hoda N: GSK3 beta inhibitors in the therapeutic development of diabetes, cancer and neurodegeneration: Past, present and future. Curr Pharm Des 23: 4332-4350, 2017.
Piazza F, Manni S, Tubi LQ, Montini B, Pavan L, Colpo A, Gnoato M, Cabrelle A, Adami F, Zambello R, and bortezomib-induced cell death. BMC Cancer 10: 526, 2010.

Synthase Kinase -3 regulates multiple myeloma cell growth. Carcinogenesis 33: 529-537, 2012.

Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee Pw: GSK-3β inhibition promotes cell death, apoptosis, and cell cycle arrest in HepG2 cells, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer 9: 132, 2009.

Gomez IN, Guidolin AV, Kim KH, Kurume T, Guo S, Holzle D, Luchini DN, Blond SY, Billadeau DD and Kozikowski AP: From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl) maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem 52: 1853-1863, 2009.

Kuroki H, Anraku T, Kazama A, Bilim V, Tasaki M, Schmitt D, Mazar A, Giles FJ, Ugolkov A and Tomita Y: 9-ING-41, a small molecule inhibitor of GSK-3β, potentiates the effects of anti-cancer therapies in bladder cancer. Exp Cell Res 389: 99977, 2019.

Kuroki T, Kuroki H, Kazama A, Bilim V, Tasaki M, Schmitt D, Mazar A, Giles FJ, Ugolkov A and Tomita Y: Clinically relevant GSK3β inhibitor 9-ING-41 is active as a single agent and in combination with other anti-tumor therapies in human renal cancer. Int J Mol Med 45: 315-323, 2020.

Ugolkov AV, Bondarenko O, Berbegall AP, Navarro S, Noguera R, O'Halloran TV, Hendrix MJ, Giles FJ and Mazar A: 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs 29: 717-724, 2018.

Kawahara R, Chulkapalli R, Gordon LJ, Borgia JA, Ugolkov A, Mazar A and Giles FJ: GSK-3β inhibitor 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents. Oncotarget 8: 114924-114934, 2017.

Ugolkov A, Gaisina I, Zhang JS, Billadeau DD, White K, Kozikowski A, Jain S, Cristofanilli M, Giles F, O'Halloran T, et al: GSK-3 inhibition overcomes chemoresistance in human breast cancer. Cancer Lett 380: 384-392, 2016.

Ugolkov A, Qiang W, Bondarenko G, Prosci D, Gaisina I, James CD, Chandler J, Kozikowski A, Gunowsewo H, O'Halloran T, et al: Combination treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU cures orthotopic chemoresistant glioblastoma in patient-derived xenograft models. Transl Oncol 10: 669-678, 2017.

Hilliard TS, Gaisina IN, Muehlbauer AG, Gaisina A, Gallier F, Kozikowski A and Burdette J: Novel glycogen synthase kinase 3beta inhibitors induce apoptosis in ovarian cancer. Biol Reprod 83 (Suppl 1): E691, 2010.
128. Fionda C, Soriani A, Zingoni A, Santoni A and Cippitelli M: NKG2D and DNAM-1 ligands: Molecular targets for NK cell-mediated immunotherapeutic intervention in multiple myeloma. Biomed Res Int 2015: 178698, 2015.

129. Fionda C, Malgarini G, Soriani A, Zingoni A, Cecere F, Iannitto ML, Ricciardi MR, Federico V, Petrucci MT, Santoni A and Cippitelli M: Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: Role of STAT3. J Immunol 190: 6662-6672, 2013.

130. Parameswaran R, Ramakrishnan P, Moreton SA, Xia Z, Hou Y, Lee DA, Gupta K, deLima M, Beck RC and Wald DN: Repression of GSK3 restores NK cell cytotoxicity in AML patients. Nat Commun 7: 11154, 2016.

131. Ciocchi F, Valamehr B, Bjordahl R, Zhang B, Rezner B, Rogers P, Gaidarova S, Moreno S, Tuininga K, Dougherty P et al.: GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity. Cancer Res 77: 5664-5675, 2017.

132. Ohteki T, Parsons M, Zakarian A, Jones RG, Nguyen LT, Woodgett JR and Ohashi PS: Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. J Exp Med 192: 99-104, 2000.

133. Taylor A and Rudd CE: Glycogen synthase kinase 3 inactivation compensates for the lack of CD28 in the priming of CD8+ cytotoxic T-cells: Implications for anti-PD-1 immunotherapy. Front Immunol 8: 1653, 2017.

134. Taylor A, Harker JA, Chanthong K, Stevenson PG, Zuniga EI and Rudd CE: Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of Co-receptor PD-1 to enhance CD8(+) cytolytic T cell responses. Immunity 44: 274-286, 2016.

135. Yu XJ, Han QB, Wen ZS, Ma L, Gao J and Zhou GB: Gambogenic acid induces G1 arrest via GSK3β-dependent cyclin D1 degradation and triggers autophagy in lung cancer cells. Cancer Cell 22: 185-194, 2012.

136. Kunnimalaiyaan S, Gamblin TC and Kunnimalaiyaan M: Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression. HPB (Oxford) 17: 770-776, 2015.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.